Levin AA - Search Results

1

The Oligonucleotide Safety Working Group (OSWG).

Schubert D, Levin AA, Kornbrust D, Berman CL, Cavagnaro J, Henry S, Seguin R, Ferrari N, Shrewsbury SB. Schubert D, et al. Among authors: levin aa. Nucleic Acid Ther. 2012 Aug;22(4):211-2. doi: 10.1089/nat.2012.0383. Nucleic Acid Ther. 2012. PMID: 22913593 No abstract available.

2

Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum.

Henry SP, Jagels MA, Hugli TE, Manalili S, Geary RS, Giclas PC, Levin AA. Henry SP, et al. Among authors: levin aa. Nucleic Acid Ther. 2014 Oct;24(5):326-35. doi: 10.1089/nat.2014.0491. Epub 2014 Aug 5. Nucleic Acid Ther. 2014. PMID: 25093529

3

Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice.

Henry SP, Taylor J, Midgley L, Levin AA, Kornbrust DJ. Henry SP, et al. Among authors: levin aa. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):473-81. doi: 10.1089/oli.1.1997.7.473. Antisense Nucleic Acid Drug Dev. 1997. PMID: 9361906

4

Assessing unintended hybridization-induced biological effects of oligonucleotides.

Lindow M, Vornlocher HP, Riley D, Kornbrust DJ, Burchard J, Whiteley LO, Kamens J, Thompson JD, Nochur S, Younis H, Bartz S, Parry J, Ferrari N, Henry SP, Levin AA. Lindow M, et al. Among authors: levin aa. Nat Biotechnol. 2012 Oct;30(10):920-3. doi: 10.1038/nbt.2376. Nat Biotechnol. 2012. PMID: 23051805 No abstract available.

5

Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.

Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, Kornbrust DJ. Henry SP, et al. Among authors: levin aa. J Pharmacol Exp Ther. 1997 May;281(2):810-6. J Pharmacol Exp Ther. 1997. PMID: 9152389

6

Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides.

Henry SP, Monteith D, Levin AA. Henry SP, et al. Among authors: levin aa. Anticancer Drug Des. 1997 Jul;12(5):395-408. Anticancer Drug Des. 1997. PMID: 9236855 Review. No abstract available.

7

Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits.

Henry SP, Denny KH, Templin MV, Yu RZ, Levin AA. Henry SP, et al. Among authors: levin aa. Birth Defects Res B Dev Reprod Toxicol. 2004 Dec;71(6):368-73. doi: 10.1002/bdrb.20024. Birth Defects Res B Dev Reprod Toxicol. 2004. PMID: 15617022

8

Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit.

Leeds JM, Henry SP, Truong L, Zutshi A, Levin AA, Kornbrust D. Leeds JM, et al. Among authors: levin aa. Drug Metab Dispos. 1997 Aug;25(8):921-6. Drug Metab Dispos. 1997. PMID: 9280399

9

Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice.

Henry SP, Denny KH, Templin MV, Yu RZ, Levin AA. Henry SP, et al. Among authors: levin aa. Birth Defects Res B Dev Reprod Toxicol. 2004 Dec;71(6):359-67. doi: 10.1002/bdrb.20023. Birth Defects Res B Dev Reprod Toxicol. 2004. PMID: 15617021

10

Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys.

Leeds JM, Henry SP, Geary R, Burckin T, Levin AA. Leeds JM, et al. Among authors: levin aa. Antisense Nucleic Acid Drug Dev. 2000 Dec;10(6):435-41. doi: 10.1089/oli.1.2000.10.435. Antisense Nucleic Acid Drug Dev. 2000. PMID: 11198927

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

141 results

Search Page